Technical Analysis for IMUX - Immunic, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.12 | 0.90% | 0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 200 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 4 hours ago |
| Reversed from Up | about 4 hours ago |
| Possible Pocket Pivot | about 5 hours ago |
| 50 DMA Resistance | about 6 hours ago |
| Rose Above Upper Bollinger Band | about 8 hours ago |
Get a Trading Assistant
- Earnings date: 08/01/2024
Immunic, Inc. Description
Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORĪ³t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Immunotherapy Clinical Development Autoimmune Disease Psoriasis Multiple Sclerosis Ulcerative Colitis Metabolism Ulcer Abdominal Pain Colitis Crohn's Disease Molecule Product Inflammatory And Autoimmune Diseases Mayo Clinic Primary Sclerosing Cholangitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.11 |
| 52 Week Low | 0.9451 |
| Average Volume | 250,202 |
| 200-Day Moving Average | 1.26 |
| 50-Day Moving Average | 1.22 |
| 20-Day Moving Average | 1.16 |
| 10-Day Moving Average | 1.09 |
| Average True Range | 0.09 |
| RSI (14) | 45.36 |
| ADX | 18.55 |
| +DI | 30.32 |
| -DI | 18.67 |
| Chandelier Exit (Long, 3 ATRs) | 1.08 |
| Chandelier Exit (Short, 3 ATRs) | 1.23 |
| Upper Bollinger Bands | 1.33 |
| Lower Bollinger Band | 0.99 |
| Percent B (%b) | 0.38 |
| BandWidth | 29.26 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0052 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.54 | ||||
| Resistance 3 (R3) | 1.57 | 1.45 | 1.47 | ||
| Resistance 2 (R2) | 1.45 | 1.35 | 1.44 | 1.45 | |
| Resistance 1 (R1) | 1.29 | 1.28 | 1.23 | 1.26 | 1.42 |
| Pivot Point | 1.17 | 1.17 | 1.15 | 1.16 | 1.17 |
| Support 1 (S1) | 1.01 | 1.07 | 0.95 | 0.98 | 0.82 |
| Support 2 (S2) | 0.89 | 1.00 | 0.88 | 0.79 | |
| Support 3 (S3) | 0.73 | 0.89 | 0.77 | ||
| Support 4 (S4) | 0.70 |
